

RESPONSE

In response to the Office Action dated June 14, 2006, in the above-identified application, Applicants elect cells expressing erbB-1 and erBb-3 (claims 1,2,6,7,9 and 10). Claims 3-5, and 8 that are directed to claims that include cells also expressing other species including EGFR are withdrawn. Applicants note that the Examiner has stated that claims 1 and 2 are generic. Upon allowance of claims 1 and 2, Applicants request that the Examiner consider the withdrawn species.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees other than those fees relating to the extension of time are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100873-1P US.

Respectfully submitted,

Name: Christine McCormack
Dated: September 13, 2006
Reg. No.: L-0065
Phone No.: 1-781-839-4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451